La ce să se aștepte pacienții români după ce polonezii de la Polpharma au cumpărat Biofarm. „România este una dintre cele mai atractive piețe din regiunea CEE”

Tamás Uri and Cătălin Vicol discussed the recent acquisition of Biofarm by Polpharma, emphasizing the strategic benefits for Romanian patients and the integration of their portfolios. The transaction, valued at approximately 257 million euros, aims to enhance access to quality medications in Romania. Both executives confirmed that all regulatory approvals were obtained prior to finalizing the deal. They highlighted Romania's attractiveness as a market and the potential for expanding the product range available to Romanian consumers. The focus remains on maintaining stable prices for medications, as they are regulated by the state.